Clinical Trial

Safety and Efficacy Study of Novel Gene Therapy ZM-02 for Retinitis Pigmentosa Patients

Study acronym: MOON
Recruiting Early Phase 1
View on ClinicalTrials.gov →
Summary
This is zM-02's safety, tOlerability, and efficacy in retinitis pigmentOsa first-in-humaN study (MOON). This trial is meant to evaluate the safety and efficacy of ZM-02 in Retinitis pigmentosa (RP) patients. Unilateral intravitreal injections (IVT) will be given into the subject's Study Eye.
Protocol Amendment History 4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2024-02-27; most recent amendment 2026-03-25.
Status change: Not Yet Recruiting → Recruiting 2024-08-13
Trial Details
NCT Number NCT06292650
Lead Sponsor Zhongmou Therapeutics
Conditions Retinitis Pigmentosa
Enrollment 12 participants
Start Date 2024-02-25
Primary Completion 2027-12-25 (estimated)
Study Completion 2028-12-25 (estimated)
Updated on ClinicalTrials.gov 2026-03-31